Edesa Biotech (EDSA) Current Assets (2013 - 2026)
Edesa Biotech (EDSA) posted Current Assets of $12.7 million for Q4 2025, up 10.46% sequentially from $11.5 million in Q3 2025, and up 513.8% YoY from $2.1 million in Q4 2024.
Edesa Biotech (EDSA) Current Assets (2013 - 2026) Analysis & Trends
Edesa Biotech has reported Current Assets for 13 years, with the latest figure at $12.7 million in Q4 2025.
- Quarterly Current Assets rose 513.8% year-over-year to $12.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $12.7 million (up 513.8% YoY) and the FY2025 annual result came in at $11.5 million, up 587.08% from the prior year.
- Current Assets rose to $12.7 million in Q4 2025 per EDSA's latest filing, from $11.5 million in the prior quarter.
- Over five years, Current Assets peaked at $21.4 million in Q1 2021 and troughed at $1.7 million in Q3 2024.
- A 5-year average of $9.9 million and a median of $9.5 million in 2021 frame the typical range for Current Assets.
- The sharpest annual moves came in 2024 and 2025: Current Assets slumped 73.97% in 2024, then jumped 587.08% in 2025.
- Over 5 years, Current Assets stood at $9.9 million in 2021, then dropped by 8.14% to $9.1 million in 2022, then sank by 40.39% to $5.4 million in 2023, then plunged by 61.75% to $2.1 million in 2024, then surged by 513.8% to $12.7 million in 2025.
- According to Business Quant data, Current Assets over the past three periods registered $12.7 million, $11.5 million, and $12.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Edesa Biotech | 43.15 Mn | 43.15 Mn | - | 10.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.78 Mn |
| Dec 31, 2025 | 12.72 Mn |
| Sep 30, 2025 | 11.51 Mn |
| Jun 30, 2025 | 12.76 Mn |
| Mar 31, 2025 | 14.39 Mn |
| Dec 31, 2024 | 2.07 Mn |
| Sep 30, 2024 | 1.68 Mn |
| Jun 30, 2024 | 3.05 Mn |
| Mar 31, 2024 | 4.24 Mn |
| Dec 31, 2023 | 5.42 Mn |
| Sep 30, 2023 | 6.44 Mn |
| Jun 30, 2023 | 6.91 Mn |
| Mar 31, 2023 | 8.13 Mn |
| Dec 31, 2022 | 9.09 Mn |
| Sep 30, 2022 | 9.09 Mn |
| Jun 30, 2022 | 15.18 Mn |
| Mar 31, 2022 | 18.00 Mn |
| Dec 31, 2021 | 9.89 Mn |
| Sep 30, 2021 | 12.09 Mn |
| Jun 30, 2021 | 14.33 Mn |